Athena Countouriotis

CIK 1571469 · President & CEO · last filed 2026-06-18

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.39M

Companies

8

Total Filings

45

Lifetime Open-Market Net

-$7.13M

Filer Profile

Reported Address
C/O AMBIT BIOSCIENCES CORPORATION
11080 ROSELLE STREET
SAN DIEGO, CA 92121
Related Filers
BIOMARIN PHARMACEUTICAL INC — 5 joint filings, latest 2026-06-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IOVA Director $8.60 $0 9 2026-06-18
BMRN Director 21,040 $65.68 $1.38M $0 4 2026-06-04
PASG Director 945 $5.00 $4.7K $309.9K 9 2026-05-21
Turning Point Therapeutics, Inc. (TPTX) Delisted President & CEO 0 $76.01 $0 -$7.44M 8 2022-08-17
Cardiff Oncology, Inc. (TROV) Delisted Director $0 2 2019-06-24
Adverum Biotechnologies, Inc. (ADVM) Delisted SVP, Chief Medical Officer 15,000 $4.36 $65.4K $0 2 2018-02-20
HALOZYME THERAPEUTICS, INC. (HTI) Delisted SVP and Chief Medical Officer 45,977 $0 8 2017-02-24
AMBIT BIOSCIENCES CORP (AMBI) Delisted Chief Medical Officer $0.54 $0 3 2014-11-12

Recent Filings · Page 2 of 5

45 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-12-28 BMRN Grant (A) +2,180 $0 EDGAR
2023-06-08 IOVA Grant (A) $0 EDGAR
2023-05-26 PASG Grant (A) $0 EDGAR
2022-08-17 Turning Point Therapeutics, Inc. (TPTX) Delisted Disp (D) −110,959 -$8.43M EDGAR
2022-06-14 IOVA Grant (A) $0 EDGAR
2022-05-31 PASG Grant (A) $0 EDGAR
2022-02-11 Turning Point Therapeutics, Inc. (TPTX) Delisted Mixed +59,429 -$107.8K EDGAR
2021-07-01 IOVA Grant (A) $0 EDGAR
2021-05-28 PASG Grant (A) $0 EDGAR
2021-02-11 Turning Point Therapeutics, Inc. (TPTX) Delisted Mixed -$8.06M EDGAR
Showing 1120 of 45
Page 2 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.